table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
antiviral and associated therapy
azithromycin Rosenberg Sekhavati Rodriguez-Molinero RECOVERY ... COALITION I Covid-19 Brazil ... Espitia-Hernandez Rashad A ... COALITION II Covid-19 Brazil ...
azvudine Ren
baloxavir marboxil Lou Y
bromhexine Ansarin Tolouian Li T
chloroquine and derivatives Rosenberg Karolyi
chloroquine Chen_chloroquine Huang Huang Chen, ChiCTR2000030054 - Chloroquine NCT04342650
hydroxychloroquine Tang HAHPS ORCHID Duke University hydroxychloroquine/azithromycine Magagnoli ... Geleris Novales RECOVERY Paccoud Sbidian ... SOLIDARITY ... Arshad ... Chen NO COVID-19 ... Kalligeros Belgian Collaborative Group on COVID-19 Abd-Elsalam Cravedi Fontana Singh CCAP-1 Duke university HCQ ARCHAIC -hydroxychloroquine PROTECT B TEACH OAHU-COVID19 HYCOVID IRCT20200428047228N1 // U07 Gonzalez ... PROTECT A Gautret et al. ChiCTR2000030054-HCQ ... IRCT20150808023559N20 IRCT20150808023559N20 NCT04376814-Group A NCT04376814-Group A NOR-Solidarity ... HC-nCoV ... Zhaowei Chen Coalition Covid-19 Brazil I ... Min NCT04333654 FACCT Trial Dubee Kamran Mahevas Yu REMAP-CAP-HCQ HYDRA ... Sarhan Sarhan
darunavir cobicistat Jun C
doxycycline Spoorthi Spoorthi
Emtricitabine/tenofovir plus colchicine plus rosuvastatin Gaitan-Duarte ...
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir IRCT20200428047228N1 // U07 Udwadia AVIFAVIR Cai -FAVIPIRAVIR Cai -FAVIPIRAVIR Lou ... Chang Chen et al. NCT04310228-FAVI ... jRCTs041190120 IRCT20150808023559N20 IRCT20150808023559N20 NCT04376814-Group A NCT04376814-Group A Calik Dabbous HM Holubar M IRCT20151227025726N14 // U07 FACCT Trial Udwadia AVIFAVIR Shenoy S NCT04542694 Ruzhentsova T Solaymani-Dodaran Shinkai Kocayigit H
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides Rosenberg Carlucci Sbidian ... Lagier Arshad ... Davido Duke university HCQ-AZI Magagnoli ... Huang
azithromycin plus hydroxychloroquine ProPAC-COVID Coalition Covid-19 Brazil I ...
ivermectin ICON Khan Soto-Becerra Spoorthi Gonzalez ... Glorial F Shahbaznejad Ahmed Chachar Chaccour Espitia-Hernandez Khan Soto-Becerra Spoorthi Bukhari Kirti Babalola RIVET-COV ... Abd-Elsalam Krolewiecki I-TECH ... Mayer Camprubi Okumuş Galan Galan
ivermectin plus doxycycline Hashim A NCT04523831 ...
lopinavir/ritonavir RECOVERY SOLIDARITY ... Nojomi Chen_lopi_rito Ader ... ELACOI ... Cao REMAP-CAP ...
Lopinavir/ritonavir plus hydroxychloroquine REMAP-CAP ...
lopinavir/ritonavir plus interferon ß-1a Ader ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
niclosamide Abdulamir
nirmatrelvir / ritonavir (Paxlovid) EPIC-SR
nitazoxanide Rocco Silva Fontanesi
opaganib Winthrop
oseltamivir Chen_oseltamivir
remdesivir NIH NIAID ACTT-1 DisCoVeRy ... remdesevir external control SOLIDARITY ... Mahajan Norwegian NOR study ... Andreas ... GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ... CAP-China ...
sofosbuvir Sali Alavi-moghaddam
sofosbuvir and daclatasvir Sadeghi Yakoot Mobarak S ... Mobarak ... Eslami
sofosbuvir and ledipasvir Elgohary Nourian A
tenofovir/emtricitabine Gaitan-Duarte ...
umifenovir (arbidol) UAIIC Nojomi Chen_arbidol ELACOI ... Yethindra ELACOI ...
zinc Patel

39 studies excluded by filtering options 2

4899 ChiCTR2000029826 (Cancelled by the investigator), 0 210excludedrisk of bias not avaialble
4905 ChiCTR2000029975, 0 2300excludednot a RCTrisk of bias not avaialble
4987 CloroCOVID19, 2020 213excludedhigh risk of bias
5209 SIMPLE (Grein), 0 2300excludednot a RCTrisk of bias not avaialble
5210 Ye et al., 2020 2990excludednot a RCTrisk of bias not avaialble
5226 Duke university (Hydroxychloroquine), 2020 210excludedrisk of bias not avaialble
5259 Duke University azithromycin, 2020 210excludedrisk of bias not avaialble
5288 Barbosa, 2020 2130excludednot a RCTrisk of bias not avaialble
5300 Raquel, 2019 210excludedrisk of bias not avaialble
5303 Jacobson, 2016 210excludedrisk of bias not avaialble
5308 Sperber, 1995 210excludedrisk of bias not avaialble
5309 Paton, 2012 210excludedrisk of bias not avaialble
5351 Mallat, 2020 2130excludednot a RCTrisk of bias not avaialble
5374 Million, 2020 2300excludednot a RCTrisk of bias not avaialble
5375 Mehra, 2020 2133excludednot a RCThigh risk of bias
5375 Mehra, 2020 2133excludednot a RCThigh risk of bias
5416 Guerin, 2020 2314excludednot a RCThigh risk of bias
5416 Guerin, 2020 2314excludednot a RCThigh risk of bias
5521 Del Amo, 2020 200excludedrisk of bias not avaialble
6080 IDEA, 2020 2100excludednot a RCTrisk of bias not avaialble
6083 IFORS (Pott-Junior), 2020 213excludedhigh risk of bias
6096 Elgazzar - treatment, 2020 213excludedhigh risk of bias
6097 Elgazzar - prophylaxis, 2020 213excludedhigh risk of bias
6098 Patel, 2020 2100excludednot a RCTrisk of bias not avaialble
6134 Morgenstern, 2020 2300excludednot a RCTrisk of bias not avaialble
6184 Erdem, 2020 2110excludednot a RCTrisk of bias not avaialble
6262 Yamamura, 2020 2300excludednot a RCTrisk of bias not avaialble
6267 Murohashi, 2020 2100excludednot a RCTrisk of bias not avaialble
6339 Delliere, 2020 2130excludednot a RCTrisk of bias not avaialble
6368 Niaee (vs placebo), 2020 213excludedhigh risk of bias
6374 NCT04425850 (Caravallo), 2020 2310excludednot a RCTrisk of bias not avaialble
6375 Cadegiani -Iver, 2020 2990excludednot a RCTrisk of bias not avaialble
6379 Chamie-Quintero,, 2020 2150excludednot a RCTrisk of bias not avaialble
6526 Dabbous, 2021 213excludedhigh risk of bias
6625 Nasir, 2020 2310excludednot a RCTrisk of bias not avaialble
6625 Nasir, 2020 2310excludednot a RCTrisk of bias not avaialble
7314 Samaha, 2021 213excludedhigh risk of bias
7995 Hazan, 2021 2320excludednot a RCTrisk of bias not avaialble
10322 Elgazzar, 0 200excludedrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons